Advances in Infectious Diseases

Volume 3, Issue 1 (March 2013)

ISSN Print: 2164-2648   ISSN Online: 2164-2656

Google-based Impact Factor: 0.77  Citations  

Evaluation of Pathogen Reduction Systems to Inactivate Dengue and Chikungunya Viruses in Apheresis Platelets Suspended in Plasma

HTML  Download Download as PDF (Size: 206KB)  PP. 1-9  
DOI: 10.4236/aid.2013.31001    5,144 Downloads   9,389 Views  Citations

ABSTRACT

The risk of blood-borne transmission of infectious diseases has led to an increasing awareness of the need for a safe and effective pathogen reduction technology. This study evaluated the efficacy of 2 pathogen reduction systems to inactivate dengue virus (DENV-2) and chikungunya virus (CHIKV) spiked into apheresis platelets (APLT) concentrates. Double-dose APLT collections (n = 3) were split evenly into two units and spiked with 107 infectious units of DENV-2 or CHIKV. APLTs samples were assayed for viral infectivity before and after Amotosalen photochemical treatment (PCT) or Riboflavin pathogen reduction treatment (PRT). Viral infectivity was determined by plaque assays. Platelet (PLT) count, pH and residual S-59 were measured during the storage of 5 days. Amotosalen PCT showed robust efficacy and complete inactivation of both viruses in APLTs, with up to 3.01 and 3.75 log reductions of DENV-2 and CHIKV respectively. At similar initial concentrations, Riboflavin PRT showed complete inactivation of CHIKV with up to 3.73 log reduction, much higher efficacy than against DENV-2 where a log reduction of up to 1.58 was observed. All post-treated APLTs maintained acceptable PLT yields and quality parameters. This parallel study of 2 pathogen reduction systems demonstrates their efficacy in inactivating or reducing DENV and CHIKV in APLTs and reaffirms the usefulness of pathogen inactivation systems to ensure the safety in PLTs transfusion.

Share and Cite:

L. Tan, S. Lam, S. Ling Low, F. Hui Tan, L. Ching Ng and D. Teo, "Evaluation of Pathogen Reduction Systems to Inactivate Dengue and Chikungunya Viruses in Apheresis Platelets Suspended in Plasma," Advances in Infectious Diseases, Vol. 3 No. 1, 2013, pp. 1-9. doi: 10.4236/aid.2013.31001.

Cited by

[1] Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays
2020
[2] The Emergence of Zoonotic Pathogens as Agents of Concern in Transfusion Medicine
Blood Safety, 2019
[3] A systematic review of individual and community mitigation measures for prevention and control of chikungunya virus
2019
[4] Amustaline (S‐303) treatment inactivates high levels of Chikungunya virus in red‐blood‐cell components
Vox Sanguinis, 2018
[5] SYBR green-based one step quantitative real-time polymerase chain reaction assay for the detection of Zika virus in field-caught mosquitoes
2017
[6] Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination
Transfusion, 2017
[7] Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione
Transfusion, 2017
[8] Inactivation of Z ika virus in plasma with amotosalen and ultraviolet A illumination
Transfusion, 2016
[9] Dengue virus persists and replicates during storage of platelet and red blood cell units
Transfusion, 2016
[10] 혈소판제제에 대한 병원체 불활화
대한수혈학회지: 제, 2016
[11] Pathogen Reduction for Platelets
The Korean Journal of Blood Transfusion, 2016
[12] Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use
Blood Transfusion, 2016
[13] Zika Virus and the Blood Supply: What Do We Know?
Transfusion Medicine Reviews, 2016
[14] Prevention of transfusion‐transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation
ISBT Science Series, 2016
[15] Inactivation of viruses in platelet and plasma products using a riboflavin‐and‐UV–based photochemical treatment
Transfusion, 2015
[16] Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination
Transfusion, 2015
[17] Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood‐derived therapies
Transfusion, 2015
[18] Pathogen inactivation: emerging indications
Current Opinion in Hematology, 2015
[19] Reflections on the emergence of chikungunya virus in the U nited S tates: time to revisit a successful paradigm for the safety of blood‐derived therapies
Transfusion, 2015
[20] Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood-derived therapies.
2015
[21] Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non‐leucoreduced platelet‐rich plasma‐derived platelets suspended in plasma
Vox sanguinis, 2014
[22] Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination
Transfusion, 2014

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.